[Prevention of recurrent myocardial infarcts by long-term aspirin therapy].
Daily 500 mg doses of aspirin were shown to be sufficient to produce lasting (one year long) inhibition of platelet aggregation. Two matched samples of postmyocardial infarction patients were compared: 844 untreated controls and 570 patients treated with 500 mg aspirin daily for 1 year following myocardial infarction. In the treated sample, the incidence of recurrent myocardial infarction, including sudden death, dropped from 13.1 to 8.9%, coronary mortality, including sudden death, from 7.2 to 4.7%, sudden death rate, from 3.2 to 1.9%, and total mortality, from 9.3 to 6.6%, as compared to the untreated sample.
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003645:Death, Sudden; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control*; D010349:Patient Compliance; D012008:Recurrence
D001241:Aspirin
Profilaktika povtornykh infarktov miokarda dlitel'nym priemom aspirina.